3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Renal Cell
71
Prostatic Neoplasms
22
Kidney Neoplasms
14
Carcinoma, Transitional Cell
9
Urinary Bladder Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Neoplasm Metastasis
6
Clear-cell metastatic renal cell carcinoma
6
Carcinoma, Hepatocellular
6
Urethral Neoplasms
4
Ovarian Neoplasms
4
Neoplasms
4
Colorectal Neoplasms
4
Triple Negative Breast Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Wilms Tumor
2
Urologic Neoplasms
2
Urogenital Neoplasms
2
Ureteral Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Recurrence
2
Penile Neoplasms
2
Pancreatic Neoplasms
2
Pain
2
Osteosarcoma
2
Melanoma
2
Interventions
pembrolizumab
7
padeliporfin
5
Nivolumab
4
Everolimus
4
Sunitinib
3
Sorafenib
3
Mitomycin
3
fludarabine
2
epothilone B
2
durvalumab
2
cabozantinib
2
Ipilimumab
2
Cyclophosphamide
2
Cisplatin
2
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
volociximab
1
vinflunine
1
sipuleucel-T
1
sargramostim
1
pemigatinib
1
palladium-bacteriopheophorbide
1
palbociclib
1
obinutuzumab
1
luprolide acetate gel depot
1
lenvatinib
1
ixabepilone
1
fludarabine phosphate
1
enzalutamide
1
belzutifan
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma
×
cabozantinib
×
Genitourinary
×
Clear all
NCT07227402
2026-06-04
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3
Recruiting
904 enrolled
NCT03937219
2025-09-10
COSMIC-313
Exelixis
Phase 3
Active not recruiting
855 enrolled
12 charts